Development of a homogeneous immunoassay for the detection of zolpidem in urine

Journal of Analytical Toxicology

Volumn 33, Issue 8, 2009, Pages 486-490

  Huynh, Kim ^a   Wang, Guohong ^a   Moore, Christine ^a   Barhate, Rehka ^a   Coulter, Cynthia ^a   Rodrigues, Warren ^a   Catbagan, Philip ^a   Soares, James ^a  

^a Immunalysis Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; BENZODIAZEPINE DERIVATIVE; DRUG ANTIBODY; ZALEPLON; ZOLPIDEM; ZOLPIDEM TARTRATE; ZOPICLONE;

ARTICLE; CROSS REACTION; DRUG DETERMINATION; DRUG URINE LEVEL; ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE; HUMAN; LIQUID CHROMATOGRAPHY; TANDEM MASS SPECTROMETRY;

EID: 70350504116     PISSN: 01464760     EISSN: 01464760     Source Type: Journal    
DOI: 10.1093/jat/33.8.486     Document Type: Article

References (16)

1. U.S. Food and Drug Administration. Fact sheet - Sleep disorders. http://fda.gov/womens/getthefacts/sleep.html (accessed December 2008).
2. Ambien CR Side Effects. http://Ambiencr.com/using-ambien/ ambien-cr-side-effects.aspx (accessed December 2008).
3. I. Gustavsen, J.G. Bramness, S. Skurtveit, A. Engeland, I. Neutel, and J. Morland. Road traffic accident risk related to prescriptions of the hypnotics zopiclone, zolpidem, flunitrazepam, and nitrazepam. Sleep Med. 9: 818-822 (2008).
4. S.U. Ito, T. Kanbayashi, T. Takemura, H. Kondo, S. Inomata, G. Szilagyi, T. Shimizu, and S. Nishino. Acute effects of zolpidem on daytime alertness, psychomotor and physical performance. Neurosci. Res. 59: 309-313 (2007).
5. T. Takayasu, Y. Ishida, A. Kimura, M. Kawaguchi, and T. Kondo. Distribution of zolpidem in body fluids and organ tissues in five autopsy cases. Forensic Toxicol. 26: 80-84 (2008).
6. L. Reidy,W. Genero, B.W. Steele, and H.C.Walls. The incidence of zolpidem use in suspected DUI drivers in Miami-Dade Florida; a comparative study using Immunalysis zolpidem ELISA kit and GC-MS screening. J. Anal. Toxicol. 32: 688-694 (2008).
7. L. Staner, S. Ertle, P. Boeijinga, G. Rinaudo, M.A. Arnal, and A. Muzet. Next-day residual effects of hypnotics in DSM-IV primary insomnia: a driving simulator study with simultaneous electroencephalogrammonitoring. Psychopharmacol. 181: 790-798 (2005).
8. A.M. Hausken, K. Furu, S. Skurtveit, A. Engeland, and J.G. Bramness. Starting insomnia treatment: the use of benzodiazepines versus z-hypnotics. A prescription database study of predictors. Eur. J. Clin. Pharmacol. 65(3): 295-301 (2009).
9. W.J. Cubala and J. Landowski. Seizure following sudden zolpidem withdrawal. Prog. Neuropsychopharmacol. Biol. Psychiatry. 31: 539-540 (2007).
10. B.K. Logan and F.J. Couper. Zolpidem and driving impairment. J. Forensic Sci. 46: 105-111 (2001).
11. J.C. Verster, E.R. Volkerts, B. Olivier, W. Johnson, and L. Liddicoat. Zolpidem and traffic safety-the important of treatment compliance. Curr. Drug Safety 2: 220-226 (2007).
12. J.C. Verster, D.S. Veldhuijzen, and E.R. Volkerts. Residual effects of sleep medication on driving ability. Sleep Med. Rev. 8: 309-325 (2004).
13. T. Roth, S.G. Hull, D.A. Lankford, R. Rosenberg, and M.B. Scharf. Low-dose sublingual zolpidem tartrate is associated with dose-related improvement in sleep onset and duration in insomnia characterized by middle-of-the-night (MOTN) awakenings. Sleep 31(9): 1277-1284 (2008).
14. A. Truchaud, B. Capolaghi, J.P. Yvert, Y. Gourmelin, G. Glikmanas, and M. Bogard. New trends for automation in immunoassays. Pure Appl. Chem. 63: 1123-1126 (1991).
15. N.T. Lu and B.G. Taylor. Drug screening and confirmation by GC-MS: comparison of EMIT II and Online KIMS against 10 drugs between US and England laboratories. Forensic Sci. Int. 157: 106-116 (2006).
16. F. Klupsch, R. Houssin, L. Humbert, M. Imbenotte, J.P. Henichart, and M. Lhermitte. Major metabolites of zolpidem: expeditious synthesis and mass spectra. Chem. Pharm. Bull. 54(9): 1318-1321 (2006).